Therapeutic Areas: Oncology

Choose Therapeutic Area
Oncology
Cardiology
Ophthalmology
Neurology
Endocrinology
Gastroenterology
Dermatology
Urology
Infectious diseases incl. Covid-19
Psychiatry
Rare diseases
20 years of delivering excellence as an oncology CRO

Cromos Pharma is a full-service CRO with extensive experience in conducting high-quality oncology trials. Our oncology expertise spans the entire clinical development cycle—from protocol design and endpoint selection to identifying patient populations and supporting dose optimization—all while adhering to the strictest regulatory standards.

We excel at fast and effective enrollment in oncology trials

One of the key challenges in oncology trials is timely patient recruitment. Cromos Pharma addresses this through a broad network of clinical sites and investigators, combined with data-driven, indication-specific recruitment strategies that accelerate enrollment while maintaining quality.

We have deep knowledge of global and regional regulatory frameworks specific to oncology trials. Our oncology CRO services include regulatory submissions, safety reporting, and ethical compliance oversight. Cromos Pharma’s experienced project managers ensure seamless execution through proprietary risk-based tools, with a strong focus on timelines, quality, and cost-efficiency.

Our medical writing team supports oncology studies with expert documentation, including clinical trial protocols, investigator brochures, study reports, and manuscripts for publication in scientific journals.

Through our integrated oncology CRO services and full-service operational model, we help sponsors bring cancer therapies to patients faster and more efficiently.

Our oncology experience includes:
    • Advanced Solid Tumors
    • Cervical Cancer
    • Chemo Induced Anorexia, Cachexia
    • Colorectal Cancer
    • Endometrial Cancer
    • Febrile Neutropenia
    • Liver Cancer
    • Melanoma
    • Myelodysplastic Syndrome
    • Non-Hodgkin Lymphoma
    • Non-Small Cell Lung Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Renal Cell Carcinoma
    • Small-Cell Lung Cancer
    • Stomach Cancer

Rare Cancers:

    • Acute Myeloid Leukemia (AML)
    • B-Cell Non-Hodgkin Lymphoma
    • Cutaneous T-Cell Lymphoma
    • Gastrointestinal Stromal Tumor (GIST)
    • Glioblastoma Multiforme (GBM)
    • Hepatocellular Carcinoma
    • Myelodysplastic Syndrome with Myelofibrosis
    • Osteosarcoma
    • Triple-Negative Breast Cancer
Cromos Pharma’s oncology expertise over the past five years
23,000
Patients
80
Studies
3,500
Clinical Sites
our Success story
A Phase III trial in Metastatic Castration-Resistant Prostate Cancer
Click to openclose
Why Cromos Pharma
  • We are the only CRO to offer “No Patients, No Payment” risk sharing program, where the sponsor pays only if we deliver on our milestones.
  • We have the scientific and clinical expertise to support your clinical studies, from early to late phase, from single- to multi-country execution strategies.
  • By leveraging our international expertise, we deliver unparalleled results through diligent feasibility analysis, rapid startup, and accelerated recruitment, while utilizing proactive risk management strategies and maintaining the highest data quality.
  • Our team has vast expertise in organizing scientific advisory board meetings of key opinion leaders, clinicians, and industry stakeholders.

Schedule a meeting

We are excited to connect with you, understand your goals, and explore how we can support your needs.

Contact us

more therapeutics